Leap Therapeutics Files 8-K on Financials
Ticker: CYPH · Form: 8-K · Filed: Mar 18, 2024 · CIK: 1509745
| Field | Detail |
|---|---|
| Company | Leap Therapeutics, INC. (CYPH) |
| Form Type | 8-K |
| Filed Date | Mar 18, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
TL;DR
Leap Therapeutics filed an 8-K, expect financial updates soon.
AI Summary
On March 18, 2024, Leap Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along with financial statements and exhibits. No specific financial figures or operational updates were detailed in the provided excerpt.
Why It Matters
This 8-K filing indicates Leap Therapeutics is providing updates on its financial condition and operational results to the SEC, which is standard for public companies.
Risk Assessment
Risk Level: low — This is a routine SEC filing for financial reporting and does not contain new material information that would inherently increase risk.
Key Players & Entities
- LEAP THERAPEUTICS, INC. (company) — Registrant
- 0001509745 (company) — Central Index Key
- 274412575 (company) — IRS Number
- 001-37990 (company) — SEC File Number
- March 18, 2024 (date) — Report Date
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Leap Therapeutics, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was this 8-K report filed?
This 8-K report was filed on March 18, 2024.
What is Leap Therapeutics, Inc.'s principal executive office address?
Leap Therapeutics, Inc.'s principal executive offices are located at 47 Thorndike Street, Suite B1-1, Cambridge, MA 02141.
What is Leap Therapeutics, Inc.'s telephone number?
Leap Therapeutics, Inc.'s telephone number, including area code, is (617) 252-4343.
What is Leap Therapeutics, Inc.'s fiscal year end?
Leap Therapeutics, Inc.'s fiscal year ends on December 31.
Filing Stats: 566 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-03-18 07:10:23
Key Financial Figures
- $0.001 — registered Common Stock, par value $0.001 LPTX Nasdaq Capital Market Indicate
Filing Documents
- tm248524d1_8k.htm (8-K) — 27KB
- tm248524d1_ex99-1.htm (EX-99.1) — 100KB
- tm248524d1_ex99-1img01.jpg (GRAPHIC) — 3KB
- 0001104659-24-035239.txt ( ) — 312KB
- lptx-20240318.xsd (EX-101.SCH) — 3KB
- lptx-20240318_lab.xml (EX-101.LAB) — 33KB
- lptx-20240318_pre.xml (EX-101.PRE) — 22KB
- tm248524d1_8k_htm.xml (XML) — 4KB
02. Results
Item 2.02. Results of Operations and Financial Condition On March 18, 2024, Leap Therapeutics, Inc. (the "Company") announced its financial results for the fourth quarter and year ended December 31, 2023. The full text of the press release issued by the Company in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02 and in the accompanying exhibit shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. The information in this Current Report on Form 8-K, including the information set forth under this Item 2.02 and the exhibit hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release of Leap Therapeutics, Inc. dated March 18, 2024. 104 Cover Page Interactive Data File. (Embedded within the Inline XBRL document.) - 2 -
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LEAP THERAPEUTICS, INC. Dated: March 18, 2024 By: /s/ Douglas E. Onsi Name: Douglas E. Onsi Title: Chief Financial Officer, General Counsel, Treasurer and Secretary